Boston receives CE mark for DBS system for use in Parkinson’s Treatment
Boston Scientific Corporation, a developer of medical devices, has received CE mark approval for use of its Vercise Deep Brain Stimulation, or DBS, System for the treatment of Parkinson's disease.
According to the company, the Vercise DBS System is the commercially available DBS system to incorporate multiple independent current control, which is designed to selectively stimulate targeted areas in the brain. This system is designed to provide physicians fine control of stimulation. The Vercise System is designed to provide comfort, control, and convenience to the clinician's practice and to patients with Parkinson's disease. It is intended to minimize side effects of stimulation by controlling current at each individual contact on the lead. In addition, the system is designed to offer patient benefits including the longest battery life available for DBS therapy and the smallest stimulator footprint, the company said. "The launch of the Vercise DBS System represents a key expansion for Boston Scientific," said Maulik Nanavaty, senior vice president and president of Boston Scientific's Neuromodulation Division. "Vercise DBS is the only system on the market able to finely control stimulation with multiple independent current control. This unique technology underscores our commitment to improving patients' lives." "The unique technology offered by the Vercise DBS System provides us with new stimulation options we have never had before," said Prof. Dr Matthies. "I look forward to seeing a positive impact in patients' quality of life." http://www.datamonitor.com